The Most Favored Nation Model fails to ensure that vulnerable Medicare beneficiaries have access to safe, unrestricted care when they need it.

(Last Updated December 16, 2020)

The Administration explicitly states that a portion of the model’s savings ‘is attributable to beneficiaries not accessing their drugs through the Medicare benefit, along with the associated lost utilization.’ To learn more about what this interim final rule language entails and what this will mean for infusion centers come January 1, 2021.

light blue background
Read NICA's Comment Letter on Most Favored Nation

December 16, 2020

light blue background
Read NICA's Statement on Most Favored Nation

December 16, 2020

light blue background
Check out our FAQs for Members on Most Favored Nation

December 16, 2020

light blue background
Read NICA's Joint Complaint Challenging Legality of the Most Favored Nation Rule

December 4, 2020

light blue background
Read NICA's Joint Press Release (December 4, 2020)

“Statement on Litigation Challenging Legality of the Administration’s Most Favored Nation Rule”

light blue background
Read NICA's Original Statement from July 2020

July 24, 2020

light blue background
Read NICA's Response to the Trump Administration's Decision to Move Forward

November 23, 2020

light blue background
Read the Centers for Medicare & Medicaid (CMS) Press Release

November 20, 2020

light blue background
View the CMS Fact Sheet

November 23, 2020

light blue background
Read the Full Rule

Public comments on the rule can be submitted through the link below and must be received no later than 60 days after publication of the IFC in the Federal Register.

light blue background
New ASPE Report on Medicare Part B Drug Spending

November 23, 2020

light blue background
Medicare Part B and International Drug Pricing

This is an ASPE report on Medicare Part B drug spending and international price comparisons.

Log in with your credentials

or    

Forgot your details?

Create Account